Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Quest Diagnostics reported strong results for the third quarter of 2025, with revenues reaching $2.82 billion, a 13.1% increase compared to the previous year.</li><li>This growth was driven by a combination of organic expansion, contributions from acquisitions, and increased demand for the company's clinical solutions.</li><li>Organic revenue grew 6.8%, indicating positive momentum in the company's core operations.</li></ul>

Quest Diagnostics reported strong results for the third quarter of 2025, with revenues reaching $2.82 billion, a 13.1% increase compared to the previous year.This growth was driven by a combination of organic expansion, contributions from acquisitions, and increased demand for the company's clinical solutions.Organic revenue grew 6.8%, indicating positive momentum in the company's core operations.

Quest Diagnostics: Focus On Implementation & Digital Integration to Improve Patient Satisfaction & Potentially Retaining Long-Term Customer Relationships!

External reports (aggregated public sources), Value Investors Club

Value Investors Club (VIC)

External reports (aggregated public sources)

Value Investors Club

Key points (machine generated)<ul><li>Quest Diagnostics is a leading diagnostic health information provider in the U.S. with projected revenues of $9.9 billion in 2024, increasing to $11.2 billion by 2026.</li><li>The company operates in a duopoly with LabCorp, granting it significant pricing power despite challenges like high fixed costs and complex reimbursement processes.</li><li>Quest's focus on dividends and share repurchases indicates strong investment appeal and potential for sustained profitability.</li></ul>This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Key points (machine generated)Quest Diagnostics is a leading diagnostic health information provider in the U.S. with projected revenues of $9.9 billion in 2024, increasing to $11.2 billion by 2026.The company operates in a duopoly with LabCorp, granting it significant pricing power despite challenges like high fixed costs and complex reimbursement processes.Quest's focus on dividends and share repurchases indicates strong investment appeal and potential for sustained profitability.This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Quest Diagnostics Inc (DGX) - Wednesday, Jul 23, 2025

Smartkarma AI, Smartkarma

αSK

Smartkarma AI

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<ul>
 <li>
<a href="https://smartkarma.com/entities/quest-diagnostics-inc-ef66c26c-8435-4227-a05b-487646ac87fa">Quest Diagnostics </a>stands as a market leader in the U.S. clinical laboratory industry, capitalizing on its immense scale, extensive network of patient service centers, and broad test menu to create a significant competitive moat.</li>
 <li>Future growth is strategically focused on higher-margin areas, including advanced diagnostics (oncology, genomics), direct-to-consumer services through its Questhealth.com platform, and strategic acquisitions to expand its geographic and service footprint.</li>
 <li>Persistent reimbursement pressure, particularly from the Protecting Access to Medicare Act (PAMA), and intense competition from Labcorp and other emerging players represent the most significant headwinds to profitability and market share.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  
Quest Diagnostics stands as a market leader in the U.S. clinical laboratory industry, capitalizing on its immense scale, extensive network of patient service centers, and broad test menu to create a significant competitive moat.
  Future growth is strategically focused on higher-margin areas, including advanced diagnostics (oncology, genomics), direct-to-consumer services through its Questhealth.com platform, and strategic acquisitions to expand its geographic and service footprint.
  Persistent reimbursement pressure, particularly from the Protecting Access to Medicare Act (PAMA), and intense competition from Labcorp and other emerging players represent the most significant headwinds to profitability and market share.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Quest Diagnostics  (DGX UN) - Sep 2025

<ul><li>Quest Diagnostics, a prominent player in the medical diagnostics sector, presented its second-quarter 2025 results, highlighting a blend of strategic growth and operational challenges.</li><li>The company's performance was marked by a notable 15.2% increase in consolidated revenues to $2.76 billion compared to the previous year, driven by organic growth and strategic acquisitions.</li><li>This growth was primarily fueled by heightened demand for advanced diagnostic solutions and expanded relationships with enterprise accounts.</li></ul>

Quest Diagnostics, a prominent player in the medical diagnostics sector, presented its second-quarter 2025 results, highlighting a blend of strategic growth and operational challenges.The company's performance was marked by a notable 15.2% increase in consolidated revenues to $2.76 billion compared to the previous year, driven by organic growth and strategic acquisitions.This growth was primarily fueled by heightened demand for advanced diagnostic solutions and expanded relationships with enterprise accounts.

Quest Diagnostics: Capitalizing On Advanced Diagnostics & Utilization Trends & Other Major Growth Drivers!

<ul><li>Quest Diagnostics reported strong results for the first quarter of 2025 with a 12% increase in revenues, primarily driven by acquisitions, organic growth, and increased demand for advanced diagnostics.</li><li>The company's strategy, focused on expanding its advanced diagnostics portfolio in key clinical areas and increasing automation and AI usage, appears to be paying dividends, as evidenced by the robust revenue growth in its physician and hospital channels.</li><li>Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.</li></ul>

Quest Diagnostics reported strong results for the first quarter of 2025 with a 12% increase in revenues, primarily driven by acquisitions, organic growth, and increased demand for advanced diagnostics.The company's strategy, focused on expanding its advanced diagnostics portfolio in key clinical areas and increasing automation and AI usage, appears to be paying dividends, as evidenced by the robust revenue growth in its physician and hospital channels.Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

Quest Diagnostics: Investment in Technology & Data Management For A Competitive Edge!

United States

Quest Diagnostics Incorporated provides diagnostic testing, information, and services.  The Company operates a national network of full-service laboratories, rapid response laboratories, and patient service centers.  Quest Diagnostics provides esoteric testing, routine medical testing, drugs of abuse testing, and non-hospital-based anatomicpathology testing.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Quest Diagnostics (DGX US)

Quest Diagnostics: Focus On Implementation & Digital Integration to Improve Patient Satisfaction & Potentially Retaining Long-Term Customer Relationships!

Quest Diagnostics reported strong results for the third quarter of 2025, with revenues reaching $2.82 billion, a 13.1% increase compared to the...

Baptista Research

Quest Diagnostics Inc (DGX) - Wednesday, Jul 23, 2025

Quest Diagnostics, a leading U.S. diagnostic provider, is poised for growth with projected revenues rising to $11.2 billion by 2026, bolstered by...

Value Investors Club (VIC)

Primer: Quest Diagnostics (DGX UN) - Sep 2025

Quest Diagnostics stands as a market leader in the U.S. clinical laboratory industry, capitalizing on its immense scale, extensive network of...

αSK

Quest Diagnostics: Capitalizing On Advanced Diagnostics & Utilization Trends & Other Major Growth Drivers!

Quest Diagnostics, a prominent player in the medical diagnostics sector, presented its second-quarter 2025 results, highlighting a blend of...

Baptista Research

Quest Diagnostics: Investment in Technology & Data Management For A Competitive Edge!

Quest Diagnostics reported strong results for the first quarter of 2025 with a 12% increase in revenues, primarily driven by acquisitions, organic...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)